	US 12,258,395 B2
	Materials and methods for treating stress-related disorders and cancer
Todd Eliot Golde, Gainesville, FL (US); Hunter S. Futch, Gainesville, FL (US); Brenda Dawn Moore, Gainesville, FL (US); and Benoit Giasson, Gainesville, FL (US)
Assigned to UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, Gainesville, FL (US)
Appl. No. 16/973,502
Filed by UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., Gainesville, FL (US)
PCT Filed Jun. 10, 2019, PCT No. PCT/US2019/036337 § 371(c)(1), (2) Date Dec. 9, 2020, PCT Pub. No. WO2019/241127, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/843,677, filed on May 6, 2019.
Claims priority of provisional application 62/777,572, filed on Dec. 10, 2018.
Claims priority of provisional application 62/683,369, filed on Jun. 11, 2018.
Prior Publication US 2021/0371514 A1, Dec. 2, 2021
Int. Cl. C07K 16/26 (2006.01); A61K 38/35 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/26 (2013.01) [A61K 38/35 (2013.01); A61K 39/001144 (2018.08); A61K 47/6415 (2017.08); A61K 47/6847 (2017.08); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01)]

8 Claims

1. An antibody or antigen binding fragment thereof that specifically binds to a region of corticotropin-releasing hormone (CRH), wherein the antibody or antigen binding fragment comprises a set of 6 CDRs set forth in SEQ ID NOs: 12-17.